查看购物车
  • Traditional Chinese
  • English
  • Japanese
非囊肿纤维化支气管扩张市场：全球药物类别与地区分析与预测（2025-2035）
市场调查报告书
商品编码
1729048

非囊肿纤维化支气管扩张市场：全球药物类别与地区分析与预测（2025-2035）

Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

非囊肿纤维化支气管扩张症 (NCFB) 的诊断是透过高解析度电脑断层扫描和肺功能测试进行的，治疗通常包括使用抗生素控制感染疾病、使用黏液溶解剂清除黏液、使用支气管扩张剂改善气流以及进行肺部復健。

透过适当的管理，包括预防感染和控制症状，患者可以改善生活质量，但这种疾病会随着时间的推移逐渐降低肺功能。

非囊肿纤维化支气管扩张症市场的主要驱动力之一是人们对该疾病的认识不断提高以及诊断水平不断提高。随着医疗保健专业人员对该疾病及其症状的了解不断加深，越来越多的患者在早期得到诊断。这一趋势得到了诊断技术的进步的支持，例如高解析度电脑断层扫描，它可以准确检测出支气管扩张的特征性气道扩张。随着人们认识的提高和诊断技术的改进，非囊肿纤维化支气管扩张已被认可为一种单独的疾病实体，从而可以更早地进行治疗并改善症状管理。这反过来又推动了对抗生素、祛痰药、支气管扩张剂和生物製药等有效治疗方法的需求，从而推动了市场成长。

然而，儘管市场不断增长，但仍存在一些挑战阻碍着进步并限制了治疗的效果。主要挑战之一是缺乏美国FDA核准的针对非囊肿纤维化支气管扩张的特定治疗方法。目前使用的许多治疗方法都是对核准治疗其他疾病（如囊肿纤维化和慢性阻塞性肺病(COPD)）的药物的仿单标示外的使用，因此很难制定标准的治疗指南。此外，生物製药、长期抗生素治疗和吸入疗法等先进治疗方法高成本，限制了人们获得治疗的机会，特别是对于低收入社区和保险不足的患者而言。

此外，由于疾病的多样性，很难制定出一种通用于所有患者的统一治疗方法。这是因为非囊肿纤维化支气管扩张在每位患者身上的表现不同，病因、严重程度和治疗反应也不同。此外，延迟诊断往往会导致严重疾病，使治疗复杂化，并限制现有治疗方法的有效性。此外，医护人员和公众缺乏意识，导致诊断延迟或被忽视，这在医疗资源有限的地区尤其严重。这些挑战强调了加速有针对性的研究、核准特定治疗方法以及改善医疗服务的必要性。

本报告调查了全球非囊肿纤维化支气管扩张市场，并总结了主要趋势、市场影响因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第 1 章。全球非囊肿纤维化支气管扩张市场：产业展望

  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 全球非囊肿纤维化支气管扩张症市场（依药物类别）

  • 抗生素
  • 皮质类固醇
  • 支气管扩张剂
  • 其他的

3. 全球非囊肿纤维化支气管扩张症市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

4. 全球非囊肿纤维化支气管扩张市场：竞争格局与公司概况

  • 主要策略和发展
  • 公司简介
    • AstraZeneca
    • Sanofi
    • Insmed
    • Boehringer Ingelheim
    • Zambon
    • Chiesi Pharmaceuticals
    • Haisco Pharmaceutical Group
    • Regeneron Pharmaceuticals

第五章调查方法

Product Code: BHL2875SA

Global Non-Cystic Fibrosis Bronchiectasis Market, Analysis and Forecast: 2025-2035

Non-Cystic fibrosis bronchiectasis (NCFB) is a chronic lung condition characterized by the permanent widening and scarring of the bronchi, the airways in the lungs. Unlike as cystic fibrosis, Non-cystic fibrosis bronchiectasis occurs in individuals without the genetic disorder and is typically caused by recurrent respiratory infections, autoimmune diseases, immunodeficiency disorders, or aspiration of food and liquids into the lungs. The condition leads to the accumulation of mucus in the airways, which makes it difficult for the body to clear bacteria and other pathogens, resulting in frequent infections, chronic cough, sputum production, and shortness of breath. While the exact cause can vary, many cases of non-cystic fibrosis bronchiectasis are associated with chronic inflammation and repeated bacterial infections. Diagnosis is made through high-resolution CT scans and lung function tests, and treatment typically involves antibiotics to manage infections, mucolytics to clear mucus, bronchodilators to improve airflow, and pulmonary rehabilitation. With proper management, including infection prevention and symptom control, patients can improve their quality of life, although the disease may progressively impair lung function over time.

One of the key drivers of the non-cystic fibrosis bronchiectasis market is the increasing awareness and improved diagnosis of the condition. As healthcare professionals gain a better understanding of non-cystic fibrosis bronchiectasis and its symptoms, more patients are being diagnosed at earlier stages.

This has been facilitated by advancements in diagnostic technologies such as high-resolution CT scans, which are able to detect airway dilation characteristic of bronchiectasis more accurately. With greater awareness and better diagnostic capabilities, there is a growing recognition of non-cystic fibrosis bronchiectasis as a distinct disease, leading to earlier treatment and better management of symptoms. As a result, the demand for effective therapies, including antibiotics, mucolytics, bronchodilators, and biologic treatments, is on the rise, driving market growth.

Despite the growth of the non-cystic fibrosis bronchiectasis market, several challenges continue to hinder its progress and the overall effectiveness of treatment. One major issue is the lack of specific FDA-approved therapies for non-cystic fibrosis bronchiectasis, with most treatments being off-label uses of drugs approved for other conditions such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). This limits treatment options and makes it harder to develop standardized treatment protocols. Another challenge is the high cost of advanced therapies, such as biologics, long-term antibiotics, and inhalation treatments, which can be prohibitively expensive, limiting access for patients, especially in low-income regions or for those without comprehensive insurance coverage.

Additionally, disease heterogeneity makes it difficult to develop one-size-fits-all therapies, as Non-cystic fibrosis bronchiectasis presents differently in various patients, with different underlying causes, severity, and response to treatment. Moreover, late-stage diagnosis often results in more severe disease, which complicates treatment and limits the effectiveness of available therapies. There is also a lack of awareness among healthcare providers and the general public, leading to delays in diagnosis and underdiagnosis, particularly in regions with limited access to healthcare resources. These challenges emphasize the need for targeted research, regulatory approval of specific therapies, and improved healthcare access to better manage non-cystic fibrosis bronchiectasis.

The global non-cystic fibrosis bronchiectasis market is highly competitive, with several leading pharmaceutical companies playing a pivotal role in advancing treatments for this chronic respiratory disease. Major players such as AstraZeneca, GlaxoSmithKline (GSK), Novartis, Boehringer Ingelheim, Pfizer, Vertex Pharmaceuticals, Genentech (Roche), Chiesi Pharmaceuticals, and Teva Pharmaceutical Industries are actively developing a range of therapies, including bronchodilators, mucolytics, antibiotics, and biologic treatments. These companies are focused on improving patient outcomes by targeting the underlying causes of non-cystic fibrosis bronchiectasis, such as chronic inflammation and recurrent infections, while also enhancing symptom management. As research in personalized medicine and novel therapies continues to evolve, these companies are positioned to significantly impact the Non-Cystic fibrosis bronchiectasis market, offering better options for those suffering from non-cystic fibrosis bronchiectasis and aiming to improve their quality of life.

Market Segmentation:

Segmentation 1: by Drug Class

  • Antibiotics
  • Corticosteroids
  • Bronchodilators
  • Others

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

The global non-cystic fibrosis bronchiectasis market is experiencing several key emerging trends that are significantly shaping the future of treatment. One of the most prominent trends is the shift towards personalized medicine, where treatments are becoming more tailored to individual patients based on their specific genetic, microbial, and disease characteristics. This approach aims to improve the effectiveness of therapies while minimizing side effects.

Additionally, there is a growing emphasis on the development of novel biologic therapies and targeted treatments that address the underlying inflammation and infection that drive the progression of non-cystic fibrosis bronchiectasis. The use of advanced diagnostics, such as high-resolution CT scans and microbial profiling, is enabling earlier and more accurate diagnosis, leading to more precise and timely interventions. Another significant trend is the increased focus on combination therapies, where medications such as bronchodilators, antibiotics, and mucolytics are used together to target multiple aspects of the disease. These trends are driving innovation in the market, offering hope for better management and improved quality of life for patients with non-cystic fibrosis bronchiectasis.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Non-Cystic Fibrosis Bronchiectasis Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Non-Cystic Fibrosis Bronchiectasis Market, by Drug Class, $Million, 2023-2035

  • 2.1 Antibiotics
  • 2.2 Corticosteroids
  • 2.3 Bronchodilators,
  • 2.4 Others

3. Global Non-Cystic Fibrosis Bronchiectasis Market (Region), ($Million), 2023-2035

  • 3.1 North America
    • 3.1.1 Key Findings
    • 3.1.2 Market Dynamics
    • 3.1.3 Market Sizing and Forecast
      • 3.1.3.1 North America Non-Cystic Fibrosis Bronchiectasis Market, by Country
        • 3.1.3.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings
    • 3.2.2 Market Dynamics
    • 3.2.3 Market Sizing and Forecast
      • 3.2.3.1 Europe Non-Cystic Fibrosis Bronchiectasis Market, by Country
        • 3.2.3.1.1 Germany
        • 3.2.3.1.2 U.K.
        • 3.2.3.1.3 France
        • 3.2.3.1.4 Italy
  • 3.3 Asia Pacific
    • 3.3.1 Key Findings
    • 3.3.2 Market Dynamics
    • 3.3.3 Market Sizing and Forecast
      • 3.3.3.1 Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market, by Country
        • 3.3.3.1.1 Japan

4. Global Non-Cystic Fibrosis Bronchiectasis Market: Competitive Landscape and Company Profiles

  • 4.1 Key Strategies and Development
    • 4.1.1 Mergers and Acquisitions
    • 4.1.2 Synergistic Activities
    • 4.1.3 Business Expansions and Funding
    • 4.1.4 Product Launches and Approvals
    • 4.1.5 Other Activities
  • 4.2 Company Profiles
    • 4.2.1 AstraZeneca
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products / Product Portfolio
      • 4.2.1.3 Top Competitors
      • 4.2.1.4 Target Customers/End-Users
      • 4.2.1.5 Key Personnel
      • 4.2.1.6 Analyst View
    • 4.2.2 Sanofi
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products / Product Portfolio
      • 4.2.2.3 Top Competitors
      • 4.2.2.4 Target Customers/End-Users
      • 4.2.2.5 Key Personnel
      • 4.2.2.6 Analyst View
    • 4.2.3 Insmed
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products / Product Portfolio
      • 4.2.3.3 Top Competitors
      • 4.2.3.4 Target Customers/End-Users
      • 4.2.3.5 Key Personnel
      • 4.2.3.6 Analyst View
    • 4.2.4 Boehringer Ingelheim
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products / Product Portfolio
      • 4.2.4.3 Top Competitors
      • 4.2.4.4 Target Customers/End-Users
      • 4.2.4.5 Key Personnel
      • 4.2.4.6 Analyst View
    • 4.2.5 Zambon
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products / Product Portfolio
      • 4.2.5.3 Top Competitors
      • 4.2.5.4 Target Customers/End-Users
      • 4.2.5.5 Key Personnel
      • 4.2.5.6 Analyst View
    • 4.2.6 Chiesi Pharmaceuticals
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products / Product Portfolio
      • 4.2.6.3 Top Competitors
      • 4.2.6.4 Target Customers/End-Users
      • 4.2.6.5 Key Personnel
      • 4.2.6.6 Analyst View
    • 4.2.7 Haisco Pharmaceutical Group
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products / Product Portfolio
      • 4.2.7.3 Top Competitors
      • 4.2.7.4 Target Customers/End-Users
      • 4.2.7.5 Key Personnel
      • 4.2.7.6 Analyst View
    • 4.2.8 Regeneron Pharmaceuticals
      • 4.2.8.1 Overview
      • 4.2.8.2 Top Products / Product Portfolio
      • 4.2.8.3 Top Competitors
      • 4.2.8.4 Target Customers/End-Users
      • 4.2.8.5 Key Personnel
      • 4.2.8.6 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Non-Cystic Fibrosis Bronchiectasis Market (by Region), $Million, 2024 and 2035
  • Figure: Global Non-Cystic Fibrosis Bronchiectasis Market Key Trends, Analysis

List of Tables

  • Table: Global Non-Cystic Fibrosis Bronchiectasis Market Dynamics, Impact Analysis
  • Table: Global Non-Cystic Fibrosis Bronchiectasis Market (by Drug Class), $Million, 2023-2035
  • Table: Global Non-Cystic Fibrosis Bronchiectasis Market (by Region), $Million, 2023-2035